Geneohm Sciences Canada, Inc.

Other

Infectio Recherche Inc.

Universitè Laval

Infectio Diagnostic, Inc.

University of California

Mission Pharmacal Company

Genohm Sciences Canada, Inc.

Michel G Bergeron

Paul H Roy

Marc Ouellette

Ann Huletsky

Maurice Boissinot

François J Picard

Andre Desormeaux

Rabeea F Omar

Francois J Picard

Christian Ménard

Christian Menard

Michel J Tremblay

Horacio Kido

Mary Ann Walter

Marc Madou

Régis Peytavi

Jian Gao

Andrew Desormeaux

André Désormeaux

Julianna Juhasz

Danielle Beaulieu

Francedillaois J Picard

Regis Peytavi

Christian M Nard

Provided herein are compositions and methods for the detection of

[object Object]

The present disclosure provides novel formulations suitable for the intravaginal delivery of tinidazole, as well as methods of using the same.

Formulations for the treatment of vaginal disorders

Methods and devices using a co-radial arrangement of serial siphon structures composed of siphon valves each separated by a capillary valve to save radial space in a fluidic system. Such serial siphon valves allow to sequentially distribute liquids in a fluidic system upon application of successive centripetal accelerations and decelerations applied to a rotary platform.

Serial siphon valves for fluidic or microfluidic devices

Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes.

Methods and probes for detecting a vancomycin resistance gene

Four highly conserved genes, encoding translation elongation factor Tu, translation elongation factor G, the catalytic subunit of proton-translocating ATPase and the RecA recombinase, are used to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical pathogens from clinical specimens for diagnosis. The detection of associated antimicrobial agents resistance and toxin genes are also under the scope of the present invention.

Highly conserved genes and their use to generate probes and primers for detection of microorganisms

Embodiments disclosed herein relate to methods and compositions for species-specific detection of bacterial and fungal nucleic acids and nucleic acids of antibiotic resistance genes.

Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories

Provided herein are methods and kits for the specific and ubiquitous detection of

The present invention relates to methods for universal bacterial detection, for specific detection of the common bacterial pathogens, and for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The core of this invention consists primarily of the DNA sequences from all species-specific genomic DNA fragments selected by hybridization from genomic libraries or, alternatively, selected from data banks as well as any oligonucleotide sequences derived from these sequences which can be used as probes or amplification primers for PCR or any other nucleic acid amplification methods. This invention also includes DNA sequences from the selected clinically relevant antibiotic resistance genes. Diagnostic kits comprising such primers and probes are also provided.

Probes and primers for detection of bacterial pathogens and antibiotic resistance genes

This invention relates to a vaginal/ano-rectal applicator for the uniform delivery of any topical formulations to treat and/or prevent any infection and/or abnormal conditions of mucosa cavity caused by any pathogen and/or disease. The present applicator comprises a longitudinally extending body that has proximal and distal ends. The proximal end is located close to the external site of a mucosal cavity accessible to a user. The body has external perforations, made as a series of slots or holes, for uniform distribution of any formulation to be delivered to the user's mucosal cavity. Upon insertion of the applicator and expulsion of the formulation in the mucosal cavity, the formulation, which is contained in a reservoir, travels through a diffusion channel having a small volume, prior to being expelled through the perforations.

Applicator for the delivery of topical formulations into mucosal cavities

A formulation is disclosed for the treatment of diseases caused by an infectious agent which acquires host membranes protein during its life cycle. The formulation is a targeting pharmaceutical composition. It comprises a ligand capable of binding the host membrane proteins coupled to a lipid-comprising vesicle, which may comprise or not a drug effective in the treatment of the disease. Specific liposomes bearing anti-HLA-DR or anti-CD4 antibodies comprising or not antiviral drugs, namely anti-HIV drugs, are disclosed and claimed. A method of formulation as well as a method of using the formulation in the treatment of a disease are also disclosed.

Methods and formulations for targeting infectious agents bearing host cell proteins

This invention relates to formulations for the prevention of infection and/or abnormal conditions of mucosae and/or skin caused by any pathogen and/or any disease, and more particularly for the prevention of sexually transmitted infections specially HIV and HSV. This invention also relates to formulations for the treatment of infection and/or abnormal conditions of skin and/or mucosac and more particularly for the treatment of herpetic lesions. The formulations could be used as a prophylactic agent to prevent accidental infection of health care workers. The formulations could be used for the healing and/or treatment of bum wounds and prevention of further infection. This invention also relates to the development of a unique vaginal/ano-rectal applicator for the uniform delivery of any topical formulations to treat and/or prevent any infection and/or abnormal conditions of mucosa cavity caused by any pathogen and/or disease.

Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities

Formulation for use in the prevention of pathogen induced diseases

The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Staphylococcus saprophyticus, Streptococcus pyogenes, Haemophilus influenzae and Moraxella catarrhalis as well as for specific detection of commonly encountered and clinically relevant bacterial antibiotic resistance genes directly from clinical specimens or, alternatively, from a bacterial colony. The above bacterial species can account for as much as 80% of bacterial pathogens isolated in routine microbiology laboratories.

Species specific and universal DNA probes and amplification primers to

The present invention relates to a method for universal detection of bacteria in biological samples and for specific detection of Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Pseudomonas aeruginosa, Proteus mirabilis, Staphylococcus saprophyticus, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae in urine or any other biological samples, said method comprising denaturation of bacterial DNA to single stranded form and either fixing it on a support or leaving it in solution, contacting said single stranded genetic material with a labeled probe selected from the group consisting of i) fragments of chromosomal DNA of the above-mentioned bacteria and ii) synthetic oligonucleotides whose sequences are derived either from the said fragments of chromosomal DNAs or from sequences available in data banks, all (i and ii) probes being capable to hybridize specifically to their chromosomal DNA or, in case of universal probes, to any bacterial chromosomal DNA.

Growing community of inventors

CA

Michel G Bergeron